Do GLP-1 drugs actually cause gastroparesis? Let's check

What did @nikkimontlick actually say?

This attorney-turned-TikToker claims that "Zembit can make your stomach stop working" and that 75% of over 3,000 pending lawsuits involve what she calls "stemic paralysis," the medical term for which is gastroparesis. Her core legal argument is that Novo Nordisk "knew that these drugs would slow down your digestive system" but failed to warn patients it could cause permanent stomach damage. She also repeatedly mispronounces the drug name and misidentifies the manufacturer, which matters when you're making legal claims on a public platform.

The video is framed as legal commentary, not medical advice, which gives her some cover. But the medical claims she makes along the way are the ones millions of GLP-1 users will actually act on, so they deserve scrutiny on their own terms.

Does the science back this up?

Partially, but with significant caveats the video glosses over. GLP-1 receptor agonists genuinely slow gastric emptying. That is a documented pharmacological effect, not a fringe lawsuit claim. But the evidence that this causes persistent or permanent gastroparesis after stopping the drug is far weaker than this video implies.

A 2023 study by Sodhi et al. in JAMA found that GLP-1 receptor agonists were associated with a roughly 3.67-fold higher risk of gastroparesis compared to bupropion/naltrexone among people using these drugs for weight loss specifically. That's a real signal. But the study measured incidence during treatment, not permanent damage after discontinuation. A 2022 review by Camilleri in Gastroenterology noted that drug-induced delayed gastric emptying is typically reversible once the offending agent is stopped. The claim that gastroparesis is permanent "even after they stop taking the drug" is not well-supported by current clinical literature. It may happen. Attributing it as a common outcome is not the same thing.

What did they get wrong (or right)?

Let's be direct. She gets the basic pharmacology directionally right: these drugs do slow gastric motility, and gastroparesis has been reported as an adverse event in real-world use and in the FDA's adverse event reporting system. The lawsuits are real. The legal theory about failure-to-warn is a legitimate legal argument being actively litigated.

But she makes three specific errors worth flagging. First, Zepbound is made by Eli Lilly, not Novo Nordisk. Novo Nordisk makes Ozempic and Wegovy. This is a basic factual error in a video explicitly making legal claims about a manufacturer. Second, the "75% of lawsuits involve gastroparesis" figure is presented without a source. The MDL litigation (In re: Ozempic/Wegovy Products Liability Litigation) involves multiple injury types, and no verified breakdown at 75% has been published in legal or medical literature. Third, framing permanent gastroparesis as a likely or common outcome overstates what the evidence currently shows.

What should you actually know?

If you are taking tirzepatide or semaglutide, gastroparesis-like symptoms, meaning nausea, vomiting, bloating, and a feeling that food isn't moving, are real and recognized side effects. The FDA label for both Ozempic and Wegovy does include warnings about delayed gastric emptying. These are not hidden risks. They are disclosed, though critics argue the severity language was initially inadequate, which is exactly what the litigation is testing.

For most patients, these GI symptoms are dose-dependent and improve over time or with dose adjustment. If you are experiencing severe or persistent symptoms, that is a conversation to have with your prescriber, not a TikTok comment section. The litigation outcome will take years and will not change your clinical management today. What matters now is that you are informed about real risks, monitored appropriately, and not scared off effective treatment by a video that inflates the permanence of a side effect for engagement.